Most-favored-nation (MFN) pricing models are fundamentally altering the economic landscape for generic drugs in the U.S., according to a finance director at Dr. Reddy's Laboratories. The policy, which ties reimbursement rates to the lowest price paid by other developed nations, is accelerating margin compression across the generics sector. The FDA estimated that generics approved in 2022 alone saved the healthcare system $18.9 billion in their first year on the market.
Those savings come at a cost to manufacturers, who face sustained deflation in retail generic prices. The Brookings Institution has noted this pricing trend, which pressures companies to maintain profitability. The Dr. Reddy's executive highlighted that MFN pricing adds another layer of uncertainty, forcing firms to adapt their cost structures and supply chain strategies.
For companies like Dr. Reddy's, the shift demands greater operational efficiency and a focus on complex generics or specialty products where pricing power is stronger. The finance director emphasized that firms must now model multiple reimbursement scenarios to navigate the volatile environment. Generic drug makers are under increasing pressure to consolidate or diversify into higher-margin biosimilars.
The broader implications extend to patient access: while MFN pricing may lower costs for payers, it could reduce the number of manufacturers for certain low-margin generics, potentially leading to shortages. The policy remains a contentious topic, with industry groups arguing it threatens long-term generic availability.